An HIV vaccine is essential for ending the HIV/AIDS pandemic

JAMA - Journal of the American Medical Association

Volumn 318, Issue 16, 2017, Pages 1535-1536

  Fauci, Anthony S ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; COMMUNITY CARE; DRUG EFFICACY; FUNDING; HEALTH CARE COST; HEALTH PROGRAM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; INFECTION RISK; NONHUMAN; NOTE; PANDEMIC; PRE-EXPOSURE PROPHYLAXIS; PRIORITY JOURNAL; SEXUAL BEHAVIOR; VIRUS LOAD; VIRUS TRANSMISSION; ACQUIRED IMMUNODEFICIENCY SYNDROME; GLOBAL HEALTH; HIV INFECTIONS; PANDEMICS;

ACQUIRED IMMUNODEFICIENCY SYNDROME; AIDS VACCINES; ANTI-HIV AGENTS; GLOBAL HEALTH; HIV INFECTIONS; HUMANS; PANDEMICS;

EID: 85032633178     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2017.13505     Document Type: Note

References (9)

1. Joint United Nations Programme on HIV/AIDS (UNAIDS). Ending AIDS. Progress towards the 90-90-90 targets. http://www.unaids.org/en /resources/documents/2017/20170720-Global -AIDS-update-2017. Published July 2017. Accessed August 15, 2017.
2. Centers for Disease Control and Prevention (CDC). Pre-Exposure Prophylaxis (PrEP). https://www.cdc.gov/hiv/risk/prep/index.html. Published 2016. Accessed August 19, 2017.
3. Giler RM, Magnuson D, Trevor H, et al. Changes in Truvada (TVD) for HIV pre-exposure prophylaxis utilization in the USA: 2012-2016. 9th International AIDS Society Conference on HIV Science, Paris, abstract WEPEC0919, July 2017. http://programme .ias2017.org/Abstract/Abstract/1614. Accessed August 15, 2017.
4. Petersen M, Balzer L, Kwarsiima D, et al. Association of implementation of a universal testing and treatment intervention with HIV diagnosis, receipt of antiretroviral therapy, and viral suppression in east Africa. JAMA. 2017;317(21): 2196-2206.
5. Coburn BJ, Okano JT, Blower S. Using geospatial mapping to design HIV elimination strategies for sub-Saharan Africa. Sci Transl Med. 2017;9(383): Eaag0019.
6. UNAIDS. Snapshot #HLM2016AIDS - HIV investments. http://www.unaids.org/sites/default /files/media-asset/HIV-investments-Snapshot-en .pdfPublished May 2016. Accessed August 19, 2017.
7. Kaiser Family Foundation and UNAIDS. Financing the response to AIDS in low- and middle-income countries: International assistance from donor governments in 2016. http://www.kff.org/global -health-policy/report/donor-government-funding -for-hiv-in-low-and-middle-income-countries-in -2016/. Published July 2017. Accessed August 15, 2017.
8. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, et al; MOPH-TAVEG Investigators. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med. 2009;361(23):2209-2220.
9. Medlock J, Pandey A, Parpia AS, Tang A, Skrip LA, Galvani AP. Effectiveness of UNAIDS targets and HIV vaccination across 127 countries. Proc Natl Acad Sci U S A. 2017;114(15):4017-4022.